Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis

M Thangarajh, J Gomez-Rial… - Multiple Sclerosis …, 2008 - journals.sagepub.com
M Thangarajh, J Gomez-Rial, AK Hedström, J Hillert, JC Alvarez-Cermeño, T Masterman…
Multiple Sclerosis Journal, 2008journals.sagepub.com
Background and Objective The presence of lipid-specific immunoglobulin M bands in the
cerebrospinal fluid (CSF) predicts an aggressive course in patients with relapsing–remitting
multiple sclerosis (MS) during early stages of the disease. This study examined whether it is
also a predictor of long-term prognosis in MS. Methods Eighty-one patients with MS and 22
headache controls were analyzed for anti-lipid IgM reactivity in CSF samples. The
correlation between the presence of lipid-specific immunoglobulin M bands in CSF and …
Background and Objective
The presence of lipid-specific immunoglobulin M bands in the cerebrospinal fluid (CSF) predicts an aggressive course in patients with relapsing–remitting multiple sclerosis (MS) during early stages of the disease. This study examined whether it is also a predictor of long-term prognosis in MS.
Methods
Eighty-one patients with MS and 22 headache controls were analyzed for anti-lipid IgM reactivity in CSF samples. The correlation between the presence of lipid-specific immunoglobulin M bands in CSF and disease progression was assessed in patients with MS who had been followed longitudinally for, on average, more than 11 years.
Results
Lipid-specific immunoglobulin M bands were detected in the CSF of 24 of 81 patients with MS and were absent in the CSF of all headache controls. Median time to conversion to a secondary progressive course was 11 years in patients with bands and 22 years in patients without bands. Median time to an Expanded Disability Status Scale score of 4 was 14 years in patients with bands and 24 years in patients without bands.
Conclusion
The presence of lipid-specific immunoglobulin M bands in CSF predicts a more adverse long-term outcome in patients with MS; it may thus define a subset of patients who might benefit from aggressive treatment during the early phase of the disease.
Sage Journals
以上显示的是最相近的搜索结果。 查看全部搜索结果